Standard BioTools Overview
- Founded
-
1999
- Status
-
Public
- Employees
-
523
- Stock Symbol
-
LAB
- Investments
-
3
- Share Price
-
$2.35
- (As of Wednesday Closing)
Standard BioTools General Information
Description
Standard BioTools Inc manufactures life science tools focused on the analysis of single cells and industrial applications of genomics. The company's segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
Contact Information
- 2 Tower Place
- Suite 2000
- San Francisco, CA 94080
- United States
Standard BioTools Timeline
Standard BioTools Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.35 | $2.45 | $0.92 - $2.65 | $192M | 78.4M | 303K | -$1.66 |
Standard BioTools Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 402,299 | 321,964 | 375,602 | 467,794 |
| Revenue | 96,563 | 97,948 | 130,581 | 138,144 |
| EBITDA | (113,510) | (173,570) | (44,266) | (34,605) |
| Net Income | (130,653) | (190,098) | (59,237) | (53,020) |
| Total Assets | 371,654 | 390,310 | 275,214 | 324,757 |
| Total Debt | 101,982 | 102,655 | 111,648 | 95,375 |
Standard BioTools Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Standard BioTools Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Standard BioTools Comparisons
Industry
Financing
Details
000 00
000000
Standard BioTools Competitors (15)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| 10x Genomics | Formerly VC-backed | Pleasanton, CA | 0000 | 00.000 | 00000000 | 00.000 |
| 00000000 | Formerly VC-backed | San Diego, CA | 00000 | 00000 | 0000000000 | 00000 |
| 0000000000 0000000 | Formerly VC-backed | Seattle, WA | 000 | 00000 | 000000 - 000 | 00000 |
| 00000 0000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
| 000000 000000 0000 | Formerly PE-Backed | Waltham, MA | 000000 | 000 | 00000000 | 000 |
Standard BioTools Patents
Standard BioTools Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20020012926-A1 | Monitoring preferential nucleotide sequences hybridization in sample; obtain nucleotide sequences and mix with probes, incubate, separate and recover hybridized nucleotide sequences | Inactive | 03-Mar-2000 | 0000000000 | |
| AU-2001240040-A1 | Combinatorial array for nucleic acid analysis | Inactive | 03-Mar-2000 | 0000000000 |
Standard BioTools Executive Team (19)
Standard BioTools Board Members (20)
| Name | Representing | Role | Since |
|---|---|---|---|
| Carlos Paya Ph.D | Self | Chairman & Board Member | 000 0000 |
| Eli Casdin | Self | Board Member | 000 0000 |
| Fenel Eloi | Self | Board Member | 000 0000 |
| Frank Witney Ph.D | Self | Board Member | 000 0000 |
| Gerhard Burbach | Self | Board Member | 000 0000 |
Standard BioTools Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Standard BioTools Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Standard BioTools Investments & Acquisitions (3)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000000 | 17-Jan-2020 | 0000000000 | 00.00 | Diagnostic Equipment | |
| 000 00000000 | 13-Feb-2014 | 0000000000 | 00000 | Other Healthcare Technology Systems | 00000 000 |
| Helicos Biosciences (Patent portfolio) | 28-Jun-2013 | Corporate Asset Purchase | 00.00 | Buildings and Property |
Standard BioTools ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
25.27 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,912
Rank
Percentile
Pharmaceuticals
Industry
00 of 965
Rank
Percentile
Laboratory Equipment and Services
Subindustry
00 of 67
Rank
Percentile
